A Cell-Based Assay for IκBα Stabilization Using A Two-Color Dual Luciferase-Based Sensor
- 1 February 2007
- journal article
- research article
- Published by Mary Ann Liebert Inc in ASSAY and Drug Development Technologies
- Vol. 5 (1) , 85-104
- https://doi.org/10.1089/adt.2006.048
Abstract
A cell-sensor assay for stabilization of IκBα was developed in the activated B cell-like diffuse large B-cell lymphoma cell line OCI-Ly3. This cell line expresses known nuclear factor κB (NFκB) target genes due to high constitutive activity of IκB kinase (IKK), which phosphorylates the protein IκBα leading to proteasomal degradation of IκBα and activation of NFκB. The cell-sensor assay uses green and red light-emitting beetle luciferases, with the green luciferase fused to IκBα (IκBα-CBG68) and the red luciferase (CBR) present in its native state. The IκBα-CBG68 reporter functions as a sensor of IKK and proteasome activity, while CBR serves to normalize for cell number and nonspecific effects. Both reporter constructs were stably integrated and placed under the control of an inducible promoter system, which increased fold responsiveness to inhibitors when assay incubations were performed simultaneous to reporter induction by doxycycline. The assay was miniaturized to a 1,536-well plate format and showed a Z′ of 0.6; it was then used to panel 2,677 bioactive compounds by a concentration–response-based screening strategy. The concentration–effect curves for the IκBα-CBG68 and CBR signals were then used to identify specific stabilizers of IκBα, such as IKK inhibitors or proteasome inhibitors, which increased the doxycycline-induced rise in IκBα-CBG68 without affecting the rise in CBR. Known and unexpected inhibitors of NFκB signaling were identified from the bioactive collection. We describe here the development and performance of this assay, and discuss the merits of its specific features.Keywords
This publication has 25 references indexed in Scilit:
- A loss-of-function RNA interference screen for molecular targets in cancerNature, 2006
- Small molecule inhibitors of IKK kinase activityExpert Opinion on Therapeutic Patents, 2005
- MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-κB-dependent proliferative advantage and resistance against FAS-induced cell death in B cellsBlood, 2005
- Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer MetastasesClinical Cancer Research, 2005
- The IKK NF-κB system: a treasure trove for drug developmentNature Reviews Drug Discovery, 2004
- Specific inhibition of gene expression using a stably integrated, inducible small‐interfering‐RNA vectorEMBO Reports, 2003
- The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma CellsThe Journal of Experimental Medicine, 2001
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Characterization of NFκB Activation by Detection of Green Fluorescent Protein-tagged IκB Degradation in Living CellsPublished by Elsevier ,1999